Myasthenia Gravis and Anxiety-Depression States: Clinical and Genetic Analysis

96 patient records from a retrospective clinical study, combined with genetic data from European population genome-wide association studies, were used to investigate the relationship between myasthenia gravis and psychiatric comorbidities. The data was uploaded by author Lijun Luo on March 18, 2026. The clinical analysis found 62.5% of patients exhibited anxiety symptoms and 46.90% presented depressive symptoms.

Use Cases

• Train models to predict anxiety risk in myasthenia gravis patients based on QMG and MG-ADL scores.
• Conduct statistical analysis on the association between disease severity scores and psychiatric symptom prevalence.
• Perform replication studies for Mendelian Randomization analysis on autoimmune and psychiatric trait relationships.
• Benchmark clinical risk models using the reported odds ratios for QMG and MG-ADL score increases.

Strengths

• Includes results from a clinical cohort of 96 myasthenia gravis patients.
• Reports specific statistical associations, such as an 11.9% higher anxiety risk per one-point QMG score increase.
• Employs a bidirectional two-sample Mendelian Randomization approach with sensitivity analyses.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the genetic association data is unknown, which may limit suitability assessment.
• The clinical cohort size of 96 patients may be limited for some analyses.

Provenance

Source

figshare, uploaded by Lijun Luo.

Collection Method

Retrospective clinical analysis of patient records and two-sample Mendelian Randomization using genome-wide association studies.

Freshness

Last updated 2026-03-18 05:34:52; freshness should be verified.

Geography

Clinical data from a single center; genetic data from European population studies.